• 1
    McGuire DB, Altomonte V, Peterson DE, et al. Patterns of mucositis and pain in patients receiving preparative chemotherapy and bone marrow transplantation. Oncol Nurs Forum 1993;20:14931502.
  • 2
    Woo SB, Sonis ST, Monopoli MM, et al.. A longitudinal study of oral ulcerative mucositis in bone marrow transplant recipients. Cancer 1993;72:16121617.
  • 3
    Elting LS, Cooksley C, Chambers M, et al. The burdens of cancer therapy. Clinical and economic outcomes of chemotherapy-induced mucositis. Cancer 2003;98:15311539.
  • 4
    Sonis ST, Oster G, Fuchs H, et al. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol 2001;19:22012205.
  • 5
    Langner S, Staber P, Schub N, et al. Palifermin reduces incidence and severity of oral mucositis in allogeneic stem-cell transplant recipients. Bone Marrow Transplant 2008;42:275279.
  • 6
    Spielberger R, Stiff P, Bensinger W, et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 2004;351:25902598.
  • 7
    Bensinger W, Schubert M, Ang KK, et al. NCCN Task Force Report. prevention and management of mucositis in cancer care. J Natl Compr Canc Netw 2008;6 Suppl 1:S1S21; quiz S22–24.
  • 8
    Cohen S. Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the new-born animal. J Biol Chem 1962;237: 15551562.
  • 9
    Brown GL, Curtsinger L,3rd, Brightwell JR, et al. Enhancement of epidermal regeneration by biosynthetic epidermal growth factor. J Exp Med 1986;163: 13191324.
  • 10
    Noguchi S, Ohba Y, Oka T. Effect of salivary epidermal growth factor on wound healing of tongue in mice. Am J Physiol 1991;260:E620E625.
  • 11
    Lee KK, Jo HJ, Hong JP, et al. Recombinant human epidermal growth factor accelerates recovery of mouse small intestinal mucosa after radiation damage. Int J Radiat Oncol Biol Phys 2008;71:12301235.
  • 12
    Wu HG, Song SY, Kim YS, et al. Therapeutic effect of recombinant human epidermal growth factor (RhEGF) on mucositis in patients undergoing radiotherapy, with or without chemotherapy, for head and neck cancer: A double-blind placebo-controlled prospective phase 2 multi-institutional clinical trial. Cancer 2009;115:36993708.
  • 13
    Stiff PJ, Emmanouilides C, Bensinger WI, et al. Palifermin reduces patient-reported mouth and throat soreness and improves patient functioning in the hematopoietic stem-cell transplantation setting. J Clin Oncol 2006;24:51865193.
  • 14
    Stiff PJ, Erder H, Bensinger WI, et al. Reliability and validity of a patient self-administered daily questionnaire to assess impact of oral mucositis (OM) on pain and daily functioning in patients undergoing autologous hematopoietic stem cell transplantation (HSCT). Bone Marrow Transplant 2006;37:393401.
  • 15
    Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 4.0, DCTD, NCI, NIH, DHHS. Available from: Accessed June 1, 2012.
  • 16
    Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207214.
  • 17
    Casagrande JT, Pike MC. An improved approximate formula for calculating sample sizes for comparing two binomial distributions. Biometrics 1978;34: 483486.
  • 18
    Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika 1983;70:659663.
  • 19
    Rosen LS, Abdi E, Davis ID, et al. Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy. J Clin Oncol 2006;24:51945200.
  • 20
    Elting LS, Shih YC, Stiff PJ, et al. Economic impact of palifermin on the costs of hospitalization for autologous hematopoietic stem-cell transplant: analysis of phase 3 trial results. Biol Blood Marrow Transplant 2007;13:806813.
  • 21
    Sonis ST, Costa JW, Jr., Evitts SM, et al. Effect of epidermal growth factor on ulcerative mucositis in hamsters that receive cancer chemotherapy. Oral Surg Oral Med Oral Pathol 1992;74:749755.
  • 22
    Soto E, Fall-Dickson JM, et al. Oral complications. In: DeVita VT, Lawrence TS, Rosenberg SA, editors. DeVita, Hellman & Rosenberg's Cancer: Principles & Practice of Oncology, 9th ed. Philadelphia, PA:Lippincott Williams & Wilkins;2011. p2338
  • 23
    Harris AL, Potter C, Bunch C, et al. Pharmacokinetics of cytosine arabinoside in patients with acute myeloid leukaemia. Br J Clin Pharmacol 1979;8:219227.
  • 24
    Hersh MR, Ludden TM, Kuhn JG, Knight WA,3rd. Pharmacokinetics of high dose melphalan. Invest New Drugs 1983;1:331334.
  • 25
    Pfluger KH, Hahn M, Holz JB, et al. Pharmacokinetics of etoposide: correlation of pharmacokinetic parameters with clinical conditions. Cancer Chemother Pharmacol 1993;31:350356.
  • 26
    Richard B, Launay-Iliadis MC, Iliadis A, et al. Pharmacokinetics of mitoxantrone in cancer patients treated by high-dose chemotherapy and autologous bone marrow transplantation. Br J Cancer 1992;65:399404.
  • 27
    Arcangelo VP, Peterson AM.Pharmacotherapeutics for Advanced Practice: A Practical Approach, 2nd edn. Philadelphia:Lippincott Williams & Wilkins Press;2006.